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INTRODUCTION
Undue delay during the diagnostic work up of patients 
with breast cancer is known to result in more adverse 
outcomes (1). Two types of delay are well recognised 
with respect to breast cancer management. The first 
type, occasioned by the patient considers time lapse 
between noticing the breast symptom and presenting 
to the healthcare provider (patient delay). The second 
being time lapse between presentation to a health 
care provider or facility and initiation of definitive 
cancer treatment (provider delay) (1,2). It has been 
consistently reported that patient delay of more 
than three months is associated with higher rates of 
recurrence and worse overall survival (3-5). Literature 
on provider delay, on the other hand is scarce and 
indeed its impact on both recurrence and overall 
survival is not clear (5). The causes of provider delay 
are complex and may include patient non-compliance, 
provider misdiagnosis and long waiting periods for 
diagnostic and therapeutic procedures owing to the 
limited capacities of healthcare systems as well as 
absence of clear diagnostic policies. Provider delay is 
indeed a measure of efficiency with which any given 
health care system delivers timely services. In addition 
it is a source of significant psychological stress to the 
patient (6). Where breast self examination (BSE) is 
widely and effectively practised, the diagnostic delays 
inherent in our healthcare systems may nullify the 
potential benefits that accrue from timely presentation 
following BSE (7). The median provider delay varies 
from 14 to 30 days in studies done in Europe and 
North America (9, 10). 
 Existing literature on provider delay mainly comes 
from the Western World with very little indeed written 
from the developing countries.Yet, it is envisaged that 
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ABSTRACT
Objective: To determine the extent and nature of provider delay in breast cancer 
management at Kenyatta National Hospital (KNH).
Design: Retrospective descriptive study. 
Setting: Kenyatta National Hospital breast clinic. 
Subjects: Records of 500 patients were reviewed over a four year period. 
Result: Out of the 500 patient files reviewed a total of 111 (22.2%) were excluded 
because either whole or part of their diagnostic work-up was done outside KNH 
(n=66) or they had recurrent disease (n=45), thus leaving 389 eligible for analysis. Mean 
overall provider delay (time lapse between the patients’ first hospital visit date to time 
definitive anti-cancer treatment was started) was 87.9 days, (n=160, range 1 to 1683 
days) and a median of 21.5 days. Nine (5.6%) patients were started on treatment three 
or more years after they initially presented to the hospital. Mean delay with regard 
to confirmatory laboratory diagnostic test was 56.2 days (n=83, range 1 to 985 days, 
standard deviation 146.7) with a median of 17.0 days. Eighty seven (22.4%) patients 
had complete data set to assess for the lapse in time from definitive diagnosis to the 
time definitive anti-cancer treatment was initiated. This mean delay was 93.5 days 
with a median of 28.0 days. 
Conclusion: The median overall provider delay for patients diagnosed with breast 
cancer at KNH is reasonable and compares well with that of other institutions. It 
remains to be determined why a small number of patients take unusually long to be 
put on definitive anti-cancer treatment. 
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provider delay may be worse in these regions, owing 
to scarcity of resources and manpower constraints. 
Quality and timely care remains a central goal of any 
breast unit specialising in breast disease management 
and any delay during diagnostic workup for cancer 
should indeed be kept to the minimum. This study 
undertook to evaluate the extent and nature of provider 
delay at KNH breast clinic. 
MATERIALS AND METHODS
Study design and setting: Retrospective descriptive 
study over a four year period from the 1st October 
2000 to 31st October 2004 carried out at Kenyatta 
National Hospital breast clinic. The KNH breast clinic 
was set up in the year 2000 as a specialist clinic for 
the purpose of managing all diseases of the breast. It 
is held once a week and run by consultant surgeons 
and surgical residents in training. 
Study population: All patients seen at the KNH breast 
clinic during the study period with cytologically or 
histologically confirmed breast cancer were included 
in this study. Patients whose diagnostic work up and/ 
or treatment were wholly or partially carried out 
outside Kenyatta National Hospital were excluded 
from the study. Also excluded were patients who 
presented for the first time at KNH breast clinic with 
recurrent disease.
Data collection: All case files and medical records 
of patients seen at the breast clinic during the 
study period and who met the inclusion criteria 
were retrieved and relevant clinico-demographic 
data entered into a structured questionnaire. Data 
collected included the date when patient was first 
seen at KNH, date first seen at the breast clinic, 
date that the confirmatory test was asked for, date 
this test was actually taken/done, the date this test 
was reported and the date the first definitive anti 
cancer treatment was initiated. (Initial anti-cancer 
treatment was accepted as surgery, radiotherapy, 
chemotherapy and/ or hormonal therapy either 
singly or in combination.
Ethical issues: Written permission to do the study was 
granted by the Kenyatta National Hospital Research 
and Ethic Committee. 
RESULTS
In this retrospective study over a four year period 
500 patients’ files were reviewed. Sixty six of these 
had part or whole of their diagnostic work up done 
in other hospitals and a further 45 patients presented 
with recurrent disease and thus were excluded 
leaving 389 eligible patients for analysis. The mean 
age was 44 years (n=389), and the range was 17 to 
99 years. Females constituted 96.6% (n=384). The 
socio-demographic characteristics of these patients 
are summarised in Table 1. Data on 160 out of the 
389 (41.1%) patients was complete for assessment of 
overall provider delay, defined as time lapse between 
when patient presented to the hospital and when 
definitive anti-cancer treatment was initiated. The 
mean overall provider delay in this study was 87.9 
days (range 1 to 1683 days and std. deviation 248.9) 
with the median of 21.5 days. Nine patients were 
started on treatment three or more years after they 
presented to the hospital. 
 Out of these 160 patients, 67 (41.9%) were started 
on treatment within 14 days (range 1 to 14 days, mean 
4.2 days, median 2.0 days, standard dev. 21.9 ). Table 
2 shows the number out of these 160 that were started 
on treatment within 30, 60 and 90 days of presenting 
at Kenyatta National Hospital 
 Out of the 389 patients 83 (21.3%) had complete 
data to assess the time it took from the date 
confirmatory laboratory request was written to the 
date it was reported. This so called mean laboratory 
delay was found to be 56.2 days (range 1 to 985.0 
days, std. dev. 146.7) with a median of 17.0 days. 
 Eighty seven (22.4%) were assessed for time lapse 
between when definitive diagnosis was made and 
when definitive anti-cancer treatment was initiated. 
This mean delay was found to be 93.5 (range 1 to 1637 
days, std dev. 228.46) and a median of 28.0 days.
Table 1
Socio- demographic characteristic of study population
                  Sex (n=384)            
Parameter    Male (%)    Female (%) Age range (years) Mean age (years) 
    (n=389)  
Statistics    13  (3.4)   371  (96.6)    17-99    44
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DISCUSSION
This study retrospectively reviewed 500 files of 
patients diagnosed with breast cancer over a four 
year period at KNH breast clinic. Sixty six files were 
excluded since part or whole of .their diagnostic 
procedures had been done in other hospitals and 
a further forty five were excluded because they 
presented with recurrent disease leaving three 
hundred and eighty nine files eligible for analysis. 
One hundred and sixty (41.1%) of the eligible group 
had complete data set for assessment of overall 
provider delay, defined as time lapse from presenting 
to the hospital and initiation of definitive anti-cancer 
treatment. The mean overall provider delay was 87.9 
days (range 1 to 1683 days and std. deviation 248.9) 
with a median of 21.5 days. This means that half 
the population under study were indeed started on 
definitive anti-cancer treatment within three weeks 
of presentation. This compares favorably well with 
studies done in other parts of the world where median 
provider delay has been found to vary from 14 to 30 
days in studies done in Europe and North America 
(9,10). In a population based study in German, Volker 
et al (5) found a median provider delay of 15 days and 
concluded that the diagnostic work up was within 
a reasonably short time limit. Nine (5.6%) patients 
in our study had curiously lengthy provider delays 
ranging from three to over five years and this is 
largely responsible for the prolonged mean provider 
delay of three months reported in this study. In our 
study only 59.4% of patients had their treatment 
initiated within 30 days and 16.3% were started on 
treatment after three months compared to 73% and 
11% respectively in the German study. 
 The extent of provider delay in any institution 
reflects the efficiency with which timely services are 
offered and where breast self examination (BSE) is 
widely and effectively practiced the diagnostic delays 
inherent in our health care systems may nullify the 
potential benefits that accrue from timely presentation 
following BSE (7). Alcoe and Gilbey (8) studied the 
experience of eight women who attended BSE classes 
and later developed breast cancer. From this study 
they concur that there is need to address the health 
care system’s response to women who present early 
on the basis of findings through BSE. 
 Determinants of provider delay are varied. 
Known factors that have been associated with 
statistically significant provider delay are the patient’s 
level of education, occupation, presentation with 
breast symptoms other than a lump, family history 
of breast cancer, employment status and mode of 
detection of breast disease. Patient non-compliance 
was found common in the more educated and 
professional woman, probably related to time 
constraints. Volker et al (5) found that women in 
full time employment had a statistically significant 
longer period for diagnostic work up. This underlies 
an important perception among these women, that 
other priorities take precedence over personal health, 
and calls for targeted education. 
 One of the physician causes of provider delay 
continues to be enthusiastic reassurance of the patient 
that a breast lesion is benign without recourse to 
biopsy. Also younger age and presentation with 
a breast symptom other than a lump were strong 
risk factors for provider delays (9). A low index 
of suspicion coupled with the opinion of low 
mammographic reliability for cancer diagnosis at 
this young age have been recognised as sources of 
physician delay (11). Although this study set out to 
explore the extent to which these factors contribute 
to provider delay, retrospectively sourced data were 
largely incomplete for meaningful analysis and a 
prospective study is therefore recommended. 
 This study looked at the delay occasioned from 
the time the laboratory request for tissue biopsy is 
written and the time the report is actually read. This 
aspect of provider delay was found to have a mean 
delay time of 56.2 days for the 83 (21.3%) patients 
whose data were complete for this assessment (range 1 
to 985.0 days, standard deviation 146.7) with a median 
of 17.0 days. This implies that though on average it 
took two months for the definitive diagnostic report 
to be available, half of the population analyzed for 
this factor, encouragingly had a report ready within 
two weeks of request. Two hundred and twenty 
seven (70%) of the diagnosis was made by fine needle 
aspiration (FNAC). The process involved in diagnostic 
Table 2
Overall provider delay within the first three months
Provider Statistical parameters
delay (days)   Cumulative mean median Std. dev. Range
 No. (%)    (days)
14 67  41.9  4.2  2.0  3.8  1 - 14 
30  95  59.4  9.3  6.0  8.8  1 - 29 
60  122  76.2  16.4  10.0  15.8  1 - 54 
90  134  83.7  21.3  14.5  21.9  1 - 86 
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reporting is that a patient has a request written and 
is then given a booking for the day that the FNAC is 
to be done after which the specimen is taken to the 
pathology laboratory for processing and reporting. 
It would be of interest to prospectively determine at 
which of these stages there is undue delay and why. 
 Also determined was the time lapse from the date 
the diagnostic report was made to the time definitive 
anti-cancer treatment was initiated. This provider 
delay had a mean of 93.5 days (range 1 to 1637 days, 
standard deviation 228.46) and a median of 28.0 days. 
The length of time taken here may reflect more of the 
way patients are booked to be reviewed with result 
and calls for a review of booking procedures. Also 
innovative ways may be employed to ensure that 
patients whose results are already out can be re-called 
earlier irrespective of their next appointment time. 
Other factors that may cause this delay include delays 
in dispatching the results to the clinic, constraints 
in theatre time leading to re-bookings and indeed 
patient non-compliance with regard to keeping 
appointments. It is recommended that prospective 
studies be done to specifically elucidate the true nature 
of provider delay with respect to these factors. 
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